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Introduction {#sec005}
============

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of fertile age \[[@pone.0226074.ref001]\]. The prevalence of PCOS ranges between 5% and 16%, depending on the ethnic groups and diagnostic criteria \[[@pone.0226074.ref002], [@pone.0226074.ref003]\]. Recent diagnostic criteria include the original National Institutes of Health (NIH), the Androgen Excess Society (AE-PCOS Society) and the new internationally endorsed Rotterdam criteria \[[@pone.0226074.ref002], [@pone.0226074.ref003]\], all of which take into account only reproductive health features such as oligo-ovulation or anovulation, hyperandrogenism, and polycystic ovaries. However, PCOS affects not only the women's sexual and reproductive health, but also their metabolic health and psychological wellbeing \[[@pone.0226074.ref004]--[@pone.0226074.ref007]\]. To date, the symptoms and features included in the Rotterdam criteria (oligomenorrhea, hirsutism/biochemical hyperandrogenism, polycystic ovaries) as well as metabolic features associated with PCOS are recognised by medical doctors internationally, whereas doctors are less aware of psychological comorbidity, such as anxiety and depression \[[@pone.0226074.ref008]--[@pone.0226074.ref010]\]. This leaves room for improvement of the awareness of comorbidities linked to PCOS, especially the psychological ones.

Previously, we reported differences in the diagnosis and treatment of PCOS across countries and between endocrinologists and obstetrician-gynecologists \[[@pone.0226074.ref010]\]. In Europe, around three-quarters of obstetrician-gynecologists and endocrinologists use the Rotterdam criteria, while in North America approximately half of these health professionals use the Rotterdam criteria, preferring the NIH criteria \[[@pone.0226074.ref010]\]. Moreover, endocrinologists are more likely to use the Rotterdam diagnostic criteria than obstetrician-gynecologists \[[@pone.0226074.ref010]\]. Reproductive and medical endocrinologists, on the other hand, are more likely to recommend lifestyle changes for the management of PCOS than obstetrician-gynecologists \[[@pone.0226074.ref010]\].

The aggregated results from many European countries on awareness and management of PCOS \[[@pone.0226074.ref010]\] cannot be generalized to the Nordic countries. There are a wide range of different health care systems in Europe. However, the Nordic countries (Finland, Denmark, Norway, Sweden and Iceland) and Estonia share similar health care systems \[[@pone.0226074.ref011]\]. Access to healthcare is high in these counties \[[@pone.0226074.ref012]\] and they are among countries with more equal distribution of income and have similarity in some lifestyle risk factors such as obesity \[[@pone.0226074.ref013]\]. To date, differences in the knowledge, diagnosis and treatment of PCOS across the Nordic countries among obstetrician-gynecologists and endocrinologists are not known. In the context of the new international guidelines for the diagnosis and management of PCOS, it is important to establish baseline practice and identify areas for improvement and translation. We aimed to study the awareness, diagnosis and management of PCOS and to determine the differences in physician characteristics in the Nordic countries and Estonia.

Materials and methods {#sec006}
=====================

Study population {#sec007}
----------------

This cross-sectional survey was conducted among medical and reproductive endocrinologists and obstetrician-gynecologists in 2015--2016. The survey questionnaire is available online \[[@pone.0226074.ref008]\] and was part of larger international study \[[@pone.0226074.ref010]\] conducted to inform translation needs for the new international PCOS guidelines that were published in 2018 \[[@pone.0226074.ref014]\]. The questionnaire and methods of the larger study have been described in detail previously. The survey questionnaire was adapted from the questionnaires used to collect data from physicians in Australia \[[@pone.0226074.ref009]\] and Europe \[[@pone.0226074.ref015]\]. The present data was partly included in the broader European group of the international study \[[@pone.0226074.ref010]\], but was not disaggregated by region (e.g., Scandinavia). We also added new data from Iceland for the analysis. In the current analysis, we report the results for each of the five Nordic countries and Estonia as well as the results for all the Nordic countries and Estonia combined. Given the European Union regulations on individual data sharing, the distribution of the link to access the questionnaire was done through the national societies (except for Iceland), i.e. the Finnish Society of Obstetrics and Gynecology, Finnish Society of Endocrinology, Danish Society of Endocrinology, Danish Society of Obstetrics and Gynecology, Norwegian Society for Gynecology and Obstetrics, Norwegian Society of Endocrinology, Estonian Gynecologists' Society. These medical societies sent an e-mail invitation to the physicians and provided the link to the questionnaire. However, the Swedish Society of Obstetrics and Gynecology did not send a personal e-mail invitation to physicians but announced the study and provided the link to the questionnaire on their website. Icelandic members of the Nordic PCOS Network identified the specialists and e-mail invitations to access the link to the questionnaire were sent through them. In the beginning of the questionnaire was a short introduction announcing that the questionnaire was sent on behalf of the Nordic PCOS network and that the questionnaire should only be replied once. The Ethical Committee of Oulu University Hospital, Oulu, Finland approved the study. Participation in this study was voluntary and the responses were given anonymously. If the participant did not report being an obstetrician-gynecologist or endocrinologist, the answers were excluded.

Independent and dependent variables {#sec008}
-----------------------------------

Information on nationality, age, gender, specialty, PCOS diagnostic criteria (the Rotterdam, NIH, AE-PCOS Society, or other) \[[@pone.0226074.ref002], [@pone.0226074.ref003]\], approximate number of women with PCOS cared for in last year, approximate national prevalence of PCOS, PCOS clinical features, psychological and psychosocial factors related to PCOS, comorbidities related to PCOS, mode of support for PCOS, and lifestyle management for PCOS was gathered by a questionnaire. The questionnaire was carried out in English.

Statistical analysis {#sec009}
--------------------

We first tested differences in physician characteristics, clinical features of PCOS, common reasons for clinic attendance, important long-term concerns, psychosocial wellbeing and comorbidities associated with PCOS, lifestyle management of PCOS, mode of support and treatment of PCOS between the countries using chi-square test. We then ran multivariable logistic regression models to identify health care provider characteristics for the following nine most important outcomes: 1) awareness of symptom improvement with weight loss, 2) estimated national PCOS prevalence, 3) using Rotterdam diagnostic criteria, 4) recommending oral contraceptive pills (OCP), 5) recommending clomiphene citrate, 6) recommending metformin plus clomiphene citrate, 7) recommending lifestyle management for non-fertility concerns, 8) recommending metformin for non-fertility concerns, and 9) recommending lifestyle management for fertility concerns. We used Stata, version 15 (StataCorp, College Station, TX) for the analyses.

Results {#sec010}
=======

Participant characteristics {#sec011}
---------------------------

The characteristics of the participants per country are presented in [Table 1](#pone.0226074.t001){ref-type="table"}. A total 382 participants were included in the analyses. Of participating physicians, 43.2% resided in Finland, 17.8% in Denmark, 16.0% in Norway, 12.8% in Estonia, 6.5% in Sweden and 3.7% in Iceland. Seventy-five percent of the participants were obstetrician-gynecologists and 25% were endocrinologists, and 79% were women. Twenty-eight percent of the physicians reported seeing more than 50 women with PCOS per year and 43% estimated the national prevalence of PCOS to be more than 10%. Over two-thirds of the physicians used the Rotterdam criteria for diagnosing PCOS.

10.1371/journal.pone.0226074.t001

###### The characteristics of the study population by country, proportions (%).
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                          Overall (N = 382)   Denmark (N = 68)   Estonia\   Finland\    Iceland (N = 14)   Norway\    Sweden\    P
                                                                                                 (N = 49)   (N = 165)                      (N = 61)   (N = 25)   
  ------------------------------------------------------- ------------------- ------------------ ---------- ----------- ------------------ ---------- ---------- ---------
  ***Sex***                                                                                                                                                      

      Men                                                 21                  30                 8          15          43                 30         32         0.001

      Women                                               79                  70                 92         85          57                 70         68         

  ***Age***                                                                                                                                                      

      ≥35                                                 17                  19                 33         15          0                  18         12         0.005

      36--45                                              30                  40                 16         30          29                 30         24         

      46--55                                              25                  15                 29         25          21                 36         16         

      ≥56                                                 28                  26                 22         30          50                 16         48         

  ***Specialty***                                                                                                                                                

      OBGYN                                               75                  55                 100        76          93                 79         60         \<0.001

      RE                                                  10                  4                  0          15          7                  2          32         

      ME                                                  15                  41                 0          9           0                  19         8          

  ***No*. *of women with PCOS cared for in last year***                                                                                                          

      \<50                                                72                  78                 88         70          71                 68         56         \<0.001

      50--200                                             26                  22                 10         30          29                 25         32         

      \>200                                               2                   0                  2          0           0                  7          12         

  ***Approximate prevalence of PCOS***                                                                                                                           

      0--10%                                              57                  48                 71         58          57                 59         48         0.21

      11--20%                                             43                  52                 29         42          43                 41         52         

  ***Diagnosis criteria used (N = 374)***                                                                                                                        

      National Institutes of Health                       3                   0                  12         4           0                  0          0          \<0.001

      Rotterdam                                           69                  79                 43         60          93                 85         92         

      AE and PCOS Society                                 2                   3                  8          0           0                  2          0          

      Do not know                                         23                  13                 33         33          7                  13         4          

      Other [\*](#t001fn002){ref-type="table-fn"}         3                   5                  4          3           0                  0          4          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ME, medical endocrinologist; OBGYN, obstetrician-gynaecologist; PCOS, polycystic ovary syndrome; RE, reproductive endocrinologist

\* Included the official diagnostic criteria or national guidelines of different countries

Clinical features, psychosocial wellbeing, lifestyle management and comorbidities {#sec012}
---------------------------------------------------------------------------------

Irregular menstrual cycle was most commonly reported clinical feature ([Table 2](#pone.0226074.t002){ref-type="table"} and [Fig 1](#pone.0226074.g001){ref-type="fig"}). In line with this, infertility was the most frequent reason for clinic attendance for PCOS in all the Nordic countries and Estonia. The second most common reason for clinic attendance was obesity and type 2 diabetes ([Table 3](#pone.0226074.t003){ref-type="table"}). Scalp hair loss was the least reported feature of PCOS ([Table 2](#pone.0226074.t002){ref-type="table"}).

![The Nordic countries health professionals' views on clinical features, comorbidities, psychosocial wellbeing and lifestyle management associated with PCOS.\
The estimates are proportions (%).](pone.0226074.g001){#pone.0226074.g001}

10.1371/journal.pone.0226074.t002

###### The differences in Nordic countries' and Estonia's health professionals' views on clinical features, psychosocial wellbeing, lifestyle management and comorbidities associated with PCOS.

The estimates are proportions (%).
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                               Overall (N = 382)   Denmark (N = 68)   Estonia\   Finland\    Iceland (N = 14)   Norway\    Sweden\    P
                                                                                                      (N = 49)   (N = 165)                      (N = 61)   (N = 25)   
  ------------------------------------------------------------ ------------------- ------------------ ---------- ----------- ------------------ ---------- ---------- ---------
  ***Clinical features (N = 382)***                                                                                                                                   

      Irregular menstrual cycles                               98                  99                 93.9       99          100                100        96         0.08

      Excess hair growth                                       88                  97                 75.5       84          93                 97         92         0.001

      Scalp hair loss                                          51                  59                 44.9       42          64                 71         48         0.003

      High blood androgen levels                               93                  99                 85.7       93          93                 92         88         0.16

      Acne                                                     87                  94                 75.5       86          79                 95         92         0.013

  ***Psychosocial wellbeing (N = 382)***                                                                                                                              

      Reduced quality of life                                  63                  78                 51         59          79                 66         56         0.02

      Depression                                               42                  57                 33         36          43                 46         40         0.05

      Anxiety                                                  24                  32                 18         21          57                 20         28         0.01

      Body image dissatisfaction                               58                  63                 50         50          86                 74         64         0.001

  ***Lifestyle management (N = 382)***                                                                                                                                

      Increased tendency for weight gain                       84                  77                 86         82          100                89         88         0.20

      Difficulty losing weight                                 79                  85                 71         75          79                 82         92         0.15

      Improvement of symptoms after weight loss                84                  93                 61         84          100                90         88         \<0.001

      Improvement of symptoms with exercise                    60                  81                 33         56          64                 67         68         \<0.001

      Improvement of symptoms with a low glycemic index diet   42                  46                 39         39          64                 51         20         0.05

  ***Comorbidities (N = 382)***                                                                                                                                       

      Reduced fertility                                        96                  94                 92         98          100                97         88         0.17

      Insulin resistance                                       97                  97                 94         99          100                97         96         0.50

      Increased risk of type 2 diabetes                        95                  96                 86         96          100                95         92         0.08

      Increased risk of gestational diabetes                   83                  74                 78         89          79                 87         72         0.03

      Increased risk of cardiovascular disease risk factors    83                  77                 76         89          79                 84         80         0.16

      Endometrial cancer                                       54                  47                 45         55          79                 53         72         0.12

      Fatty liver                                              36                  40                 16         50          21                 21         24         \<0.001

      Pregnancy complications                                  53                  49                 47         49          79                 74         44         0.004

      Sleep apnea and snoring                                  34                  31                 27         38          29                 41         20         0.26
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

10.1371/journal.pone.0226074.t003

###### The differences in Nordic countries' and Estonia's health professionals' views on most common reason for clinic attendance, most important long-term concern about PCOS, and mode of support.

The estimates are proportions (%).
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  Health professionals' views                                 Overall   Denmark   Estonia   Finland   Iceland   Norway   Sweden   P
  ----------------------------------------------------------- --------- --------- --------- --------- --------- -------- -------- -------
  The most common reason for clinic attendance (N = 378)                                                                          
      Infertility                                             77.3      70.6      95.9      77.3      69.2      75.4     66.7     0.019
      Cardiovascular diseases                                 0.8       1.5       2.0       0.6       0         0        0        0.81
      Obesity and type 2 diabetes                             13.8      20.6      16.3      14.1      0         9.8      4.2      0.17
      Endometrial cancer                                      1.3       0         2.0       2.5       0         0        0        0.54
      Psychosocial problems                                   2.7       2.9       2.0       0.6       0         8.2      4.2      0.061
  The most important long-term concern about PCOS (N = 380)                                                                       
      Infertility                                             15.5      10.5      36.7      15.2      7.7       11.5     4.0      0.001
      Cardiovascular diseases                                 12.9      9.0       6.1       17.0      15.4      11.5     12.0     0.35
      Obesity and type 2 diabetes                             63.4      71.6      46.9      62.4      76.9      63.9     72.0     0.088
      Endometrial cancer                                      5.8       6.0       8.2       4.9       0         6.6      8.0      0.86
      Psychosocial problems                                   1.3       1.5       0         0         0         4.9      4.0      0.062
  Mode of support (N = 379)                                                                                                       
      Broadly available educational materials for HPs         81        77        76        81        93        83       80       0.71
      Presentation at HP forums and workshops                 58        44        57        59        64        67       68       0.12
      A PCOS website for HPs                                  50        52        57        37        64        65       68       0.001
      A regular email update for HPs                          28        32        33        22        29        37       24       0.25
      Resources for women with PCOS                           57        53        65        51        86        65       56       0.06

HPs, health professionals

Tendency to gain weight and trouble losing weight in affected women was commonly recognized as well as the effect of weight loss and exercise on PCOS symptoms. The most commonly reported comorbidities were reduced fertility, type 2 diabetes, gestational diabetes, insulin resistance, and cardiovascular disease risk factors. Compared to other features related to PCOS, the reduction of psychosocial wellbeing in PCOS was less recognized by the health professionals. Indeed, depression and especially anxiety were commonly ranked low in the context of psychosocial features of PCOS. On the other hand, reduced quality of life was most commonly reported in Denmark, Finland and Estonia, while body image dissatisfaction was most commonly reported in Iceland, Norway and Sweden. Fatty liver, sleep apnea, pregnancy complications and risk for endometrial cancer were less commonly known features. Physicians in Finland were more aware of risk for fatty liver in women with PCOS compared with physicians in other Nordic countries and Estonia. Physicians in Norway and Iceland reported pregnancy complications more commonly than in other countries. The doctors were generally well informed that ovarian cancer is not related to PCOS ([Fig 1](#pone.0226074.g001){ref-type="fig"}). Sixteen percent of the participants reported an association between surgery for ovarian cysts and PCOS ([Fig 1](#pone.0226074.g001){ref-type="fig"}). There were no differences between the countries. Fifty-eight percent of the participants thought PCOS is underdiagnosed and 23% thought it is overdiagnosed.

The physicians ranked long-term health concerns related to PCOS as obesity, type 2 diabetes, infertility and cardiovascular diseases most important, whereas psychological wellbeing and endometrial cancer were not ranked important ([Table 3](#pone.0226074.t003){ref-type="table"}).

Treatment of PCOS {#sec013}
-----------------

OCP and lifestyle modifications were the most commonly prescribed treatments for non-fertility concern in all the countries, except Estonia, where metformin was the second most commonly prescribed treatment after OCP for non-fertility concern ([Table 4](#pone.0226074.t004){ref-type="table"}). For fertility concern, lifestyle modification was the most commonly prescribed treatment in Denmark, Estonia, Finland and Norway, and ovulation inductors in Iceland and Sweden.

10.1371/journal.pone.0226074.t004

###### Treatments most commonly prescribed for non-fertility-related and fertility-related PCOS concerns.
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  Characteristic                                                                  Overall   Denmark   Estonia   Finland   Iceland   Norway   Sweden   P
  ------------------------------------------------------------------------------- --------- --------- --------- --------- --------- -------- -------- ---------
  ***Treatments most commonly prescribed for nonfertility concerns (N = 379)***                                                                       
      Anti-androgens                                                              12        6         27        10        8         15       13       0.02
      Laser depilation                                                            6         15        0         3         0         7        8        0.005
      Lifestyle modifications                                                     66        75        59        63        62        72       58       0.31
      Metformin                                                                   45        59        65        36        54        48       21       \<0.001
      Oral contraceptives                                                         72        82        76        71        92        59       63       0.02
  ***Treatments most commonly prescribed for fertility concerns (N = 361)***                                                                          
      Clomiphene citrate                                                          32        18        29        37        31        31       41       0.11
      Clomiphene citrate with metformin                                           29        11        57        28        8         31       23       \<0.001
      Lifestyle modifications                                                     56        69        49        52        46        61       50       0.16
      Metformin                                                                   36        53        37        31        38        39       14       0.01
      Ovulation inductors                                                         25        15        29        24        77        12       55       \<0.001

Multivariable regression analysis {#sec014}
---------------------------------

Female physicians were 2.6 times more likely to estimate the national prevalence of PCOS more than 10% than male physicians ([Table 5](#pone.0226074.t005){ref-type="table"}). Physicians aged ≤35 years were twice more likely to estimate the national prevalence of PCOS more than 10% than physicians aged ≥56 ([Table 5](#pone.0226074.t005){ref-type="table"}). The physicians aged ≤35 years also 2.2 times more often recommended lifestyle management for patients with PCOS for fertility concerns than older physicians.

10.1371/journal.pone.0226074.t005

###### Multivariable models on the associations of physician characteristics with PCOS knowledge and practices.
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  Characteristic              Awareness of symptom improvement with weight loss   Estimated national PCOS prevalence \> 10%   Using Rotterdam diagnostic criteria   Recommend OCP       Recommend lifestyle management for nonfertility concerns   Recommend metformin for nonfertility concerns   Recommend lifestyle management for fertility concerns   Recommend clomiphene citrate   Recommend metformin plus clomiphene citrate
  --------------------------- --------------------------------------------------- ------------------------------------------- ------------------------------------- ------------------- ---------------------------------------------------------- ----------------------------------------------- ------------------------------------------------------- ------------------------------ ---------------------------------------------
  Sex                                                                                                                                                                                                                                                                                                                                                                                     
      Men                     1                                                   1                                           1                                     1                   1                                                          1                                               1                                                       1                              1
      Women                   1.10 (0.50--2.42)                                   2.62 (1.45--4.74)                           0.73 (0.40--1.34)                     0.93 (0.51--1.67)   1.69 (0.96--2.99)                                          1.21 (0.69--2.13)                               0.98 (0.56--1.69)                                       0.71 (0.38--1.32)              0.97 (0.52--1.84)
  Age                                                                                                                                                                                                                                                                                                                                                                                     
      ≥35                     1.62 (0.66--4.00)                                   2.06 (1.09--3.91)                           1.53 (0.76--3.05)                     0.98 (0.46--2.06)   0.91 (0.46--1.81)                                          1.69 (0.88--3.23)                               2.20 (1.13--4.30)                                       0.64 (0.30--1.33)              1.41 (0.70--2.86)
      36--45                  1.12 (0.52--2.40)                                   1.27 (0.71--2.27)                           1.55 (0.84--2.86)                     1.02 (0.53--1.99)   0.58 (0.32--1.06)                                          1.18 (0.67--2.06)                               1.10 (0.62--1.94)                                       0.69 (0.37--1.28)              0.79 (0.41--1.53)
      46--55                  1.34 (0.60--3.01)                                   1.08 (0.58--1.99)                           1.11 (0.59--2.10)                     0.41 (0.22--0.76)   1.12 (0.59--2.11)                                          1.00 (0.54--1.85)                               1.07 (0.59--1.93)                                       1.03 (0.55--1.93)              0.93 (0.47--1.83)
      ≥56                     1                                                   1                                           1                                     1                   1                                                          1                                               1                                                       1                              1
  Specialty                                                                                                                                                                                                                                                                                                                                                                               
      OBGYN/ RE               1                                                   1                                           1                                     1                   1                                                          1                                               1                                                       1                              1
      ME                      3.23 (1.09--9.59)                                   1.55 (0.80--3.01)                           1.03 (0.53--2.00)                     0.47 (0.24--0.89)   3.62 (1.62--8.08)                                          5.05 (2.51--10.16)                              1.53 (0.78--3.02)                                       0.12 (0.04--0.38)              0.26 (0.09--0.71)
  Annual patients with PCOS                                                                                                                                                                                                                                                                                                                                                               
      \<50                    1                                                   1                                           1                                     1                   1                                                          1                                               1                                                       1                              1
      ≥50                     1.93 (0.97--3.85)                                   2.48 (1.52--4.06)                           3.05 (1.67--5.58)                     0.80 (0.46--1.37)   1.41 (0.84--2.38)                                          1.19 (0.74--1.93)                               0.90 (0.56--1.45)                                       0.76 (0.46--1.28)              1.14 (0.68--1.91)

ME, medical endocrinologist; OBGYN, obstetrician-gynaecologist; PCOS, polycystic ovary syndrome; RE, reproductive endocrinologist

Odds ratios adjusted for sex, age, specialty and annual patients with PCOS, and controlled for country as a cluster

Physicians aged 46--55 years were less likely to recommend OCP for patients with PCOS than physicians aged ≥56. Medical endocrinologists more commonly recommended lifestyle management or metformin for PCOS for non-fertility concerns than obstetrician-gynecologists or reproductive endocrinologists. Physicians who treated more than 50 patients with PCOS annually, reported the national prevalence of PCOS \>10% 2.5 times more frequently and used the Rotterdam diagnostic criteria three times more frequently than physicians who treated less than 50 patients with PCOS annually.

Mode of support {#sec015}
---------------

[Table 3](#pone.0226074.t003){ref-type="table"} shows the health professionals views on mode of support that should be offered. The most common and least common modes of support were considered similar across all countries; the most needed mode of support was broadly available educational materials for health professionals and the least common mode was a regular email update. A need for PCOS specific website for health professionals was not ranked high especially in Finland compared to other countries.

Discussion {#sec016}
==========

Main findings {#sec017}
-------------

This is the first study assessing PCOS awareness in health professionals across Nordic countries and Estonia. Over two-thirds of the physicians who answered the questionnaire in the Nordic countries and Estonia use the Rotterdam diagnostic criteria for PCOS. Clinical features, lifestyle management and comorbidities are commonly recognized in women with PCOS, while the reduction of psychosocial wellbeing is less associated with PCOS. Infertility is the most frequent reason and obesity and type 2 diabetes the second most common reason for clinic attendance for PCOS in the Nordic countries and Estonia. There are some differences in the treatments for PCOS between physicians in the Nordic countries and Estonia even though the countries share similar health care systems. Younger physicians more often recommend lifestyle management for patients with PCOS for fertility concerns than older physicians that is also in line with the recommendation of the International PCOS guideline \[[@pone.0226074.ref016]\].

Previous studies, ours included, have found that depression and anxiety \[[@pone.0226074.ref006], [@pone.0226074.ref017]\] and psychological stress \[[@pone.0226074.ref018]\] are more prevalent in women with PCOS even beyond fertile age compare to non-PCOS counterparts. Moreover, women with PCOS have poorer quality of life than women without the syndrome \[[@pone.0226074.ref019]\]. Even though the data on mental health is not new, the current study shows that physicians are not well aware of coexistence of depression and anxiety and reduced quality of life in women with PCOS. This is in line with previous studies. Indeed, Australian primary care physicians did not consider psychological and metabolic comorbidities as clinical features of PCOS \[[@pone.0226074.ref009]\]. Moreover, North-American obstetrician-gynecologists were less aware of anxiety, depression and reduced quality of life in women with PCOS \[[@pone.0226074.ref008]\]. In a study conducted among the members of the European Society of Endocrinology \[[@pone.0226074.ref015]\], 64% of endocrinologists regarded obesity and type 2 diabetes as the primary long-term concerns for PCOS, 20% infertility, 12% cardiovascular diseases, 3% psychological problems and 1% considered endometrial cancer. Given all this and the fact that the risk for psychological distress among women with PCOS is 2-fold \[[@pone.0226074.ref006], [@pone.0226074.ref020]\], screening women with PCOS for psychological comorbidities is recommended.

The present study showed inconsistent management of PCOS across the Nordic countries and Estonia. Gaps in physicians' management of PCOS have also been reported in other studies \[[@pone.0226074.ref008]\]. In North America, reproductive endocrinologists recommend lifestyle changes for management of PCOS more often than obstetrician-gynecologists, whereas we found that younger doctors were more likely to offer lifestyle management compared to older colleagues. Also discipline differences were noted as medical endocrinologists were more likely to prescribe metformin than OCPs, although they are not mutually exclusive as suggested by the new PCOS guideline. The choice of treatment for the health care professional is likely influenced by the symptom the woman deems most crucial and concerning but also by the awareness and updates available of the current treatment guidelines. The current questionnaire was fulfilled just before the PCOS guideline was launched, and the results indicate that the health professionals would benefit from getting more information and education. The new international PCOS guideline and the implementations process aims to improve these aspects \[[@pone.0226074.ref014]\].

Limitations {#sec018}
-----------

The current research was a multinational and multi-disciplinary study and used a novel questionnaire for a common syndrome. However, the number of physicians who took part in this study particularly in Sweden, was small, and the study had low statistical power to estimate reliably the physicians' knowledge and management of PCOS in each country. The number of respondents from Sweden was smaller than expected, whereas the number of targeted physicians in Iceland is small altogether. Finnish physicians participated in this study more than physicians of other Nordic countries. The study was conducted by a Finnish research group, which explains the larger number of Finnish participants. Due to a small number of reproductive endocrinologists, we combined obstetricians/gynecologists and reproductive endocrinologists into a single group in the multivariable models. In the Nordic countries, a reproductive endocrinologist is a gynaecologist with additional training in infertility treatment. In Denmark, Finland and Sweden, reproductive endocrinology is recognized as a subspecialty of gynecology. In the current study, reproductive endocrinologists more often used Rotterdam diagnostic criteria than obstetricians/gynecologists (adjusted OR = 7.3, CI 1.7--31.5). However, other PCOS knowledge and practices did not differ between obstetricians/gynecologists and reproductive endocrinologists. Taking this into account, the findings may not represent obstetrician-gynecologists' and endocrinologists' awareness, diagnosis and management of PCOS in the entire country or within the disciplinary, but offers an overview of PCOS awareness in the Nordic countries and Estonia. It is possible that the results are also affected by a selection bias as the health professionals that are aware of the syndrome are more likely to answer the questionnaire. If this would be the case it would underline the need for more information and the new international PCOS guideline. The questionnaire also lacked the questions on the use of insulin sensitizers to reduce insulin resistance and aromatase inhibitors to induce ovulation. Insulin resistance and compensatory hyperinsulinemia are present in women with PCOS and insulin sensitizing drugs such as inositols are effective in improving PCOS symptoms \[[@pone.0226074.ref021], [@pone.0226074.ref022]\].

Conclusions {#sec019}
-----------

The findings of the present study suggest that the obstetrician-gynecologists, reproductive and medical endocrinologists in Nordic countries and Estonia do not consistently use Rotterdam diagnostic criteria and are not fully aware of some common comorbidities associated with PCOS, particularly psychosocial comorbidities. Furthermore, the management of PCOS seemed to be inconsistent between different physician groups. Considering these and other findings internationally, doctors need more information and education on PCOS. For universal diagnosis and treatment of PCOS, the recently published international PCOS guidelines are well needed and welcomed. Future efforts should be made to increase the awareness of the guidelines and to promote implementation into practice.

10.1371/journal.pone.0226074.r001
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